Literature DB >> 17033968

Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.

Marcus G Pezzolesi1, Yan Li, Xiao-Ping Zhou, Robert Pilarski, Lei Shen, Charis Eng.   

Abstract

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) encodes a tumor-suppressor phosphatase frequently mutated in both sporadic and heritable forms of human cancer. Germline mutations are associated with a number of heritable cancer syndromes that are jointly referred to as the "PTEN hamartoma tumor syndrome" (PHTS) and include Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome. Germline PTEN mutations have been identified in a significant proportion of patients with PHTS; however, there are still many individuals with classic diagnostic features for whom mutations have yet to be identified. To address this, we took a haplotype-based approach and investigated the association of specific genomic regions of the PTEN locus with PHTS. We found this locus to be characterized by three distinct haplotype blocks 33 kb, 65 kb, and 43 kb in length. Comparisons of the haplotype distributions for all three blocks differed significantly among patients with PHTS and controls (P=.0098, P<.0001, and P<.0001 for blocks 1, 2, and 3, respectively). "Rare" haplotype blocks and extended haplotypes account for two-to-threefold more PHTS chromosomes than control chromosomes. PTEN mutation-negative patients are strongly associated with a haplotype block spanning a region upstream of PTEN and the gene's first intron (P=.0027). Furthermore, allelic combinations contribute to the phenotypic complexity of this syndrome. Taken together, these data suggest that specific haplotypes and rare alleles underlie the disease etiology in these sample populations; constitute low-penetrance, modifying loci; and, specifically in the case of patients with PHTS for whom traditional mutations have yet to be identified, may harbor pathogenic variant(s) that have escaped detection by standard PTEN mutation-scanning methodologies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033968      PMCID: PMC1698555          DOI: 10.1086/508943

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  32 in total

1.  GOLD--graphical overview of linkage disequilibrium.

Authors:  G R Abecasis; W O Cookson
Journal:  Bioinformatics       Date:  2000-02       Impact factor: 6.937

2.  THE INTERACTION OF SELECTION AND LINKAGE. II. OPTIMUM MODELS.

Authors:  R C LEWONTIN
Journal:  Genetics       Date:  1964-10       Impact factor: 4.562

3.  Use of unphased multilocus genotype data in indirect association studies.

Authors:  David Clayton; Juliet Chapman; Jason Cooper
Journal:  Genet Epidemiol       Date:  2004-12       Impact factor: 2.135

4.  Association of the phosphatase and tensin homolog gene (PTEN) with smoking initiation and nicotine dependence.

Authors:  Lan Zhang; Kenneth S Kendler; Xiangning Chen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-01-05       Impact factor: 3.568

5.  Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation.

Authors:  A Loffeld; N J McLellan; T Cole; S J Payne; D Fricker; C Moss
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

6.  Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.

Authors:  Christopher A Haiman; Daniel O Stram; Iona Cheng; Elena E Giorgi; Loreall Pooler; Kathryn Penney; Loïc Le Marchand; Brian E Henderson; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

7.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome.

Authors:  J M Carethers; F B Furnari; A F Zigman; J E Lavine; M C Jones; G E Graham; A S Teebi; H J Huang; H T Ha; D P Chauhan; C L Chang; W K Cavenee; C R Boland
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

9.  The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers.

Authors:  J A Hamilton; L M Stewart; L Ajayi; I C Gray; N E Gray; K G Roberts; G J Watson; A V Kaisary; D Snary
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

Review 10.  Long-range control of gene expression: emerging mechanisms and disruption in disease.

Authors:  Dirk A Kleinjan; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2004-11-17       Impact factor: 11.025

View more
  6 in total

1.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 2.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

Authors:  M Christine Hollander; Gideon M Blumenthal; Phillip A Dennis
Journal:  Nat Rev Cancer       Date:  2011-04       Impact factor: 60.716

3.  Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes.

Authors:  Carol J Henderson; Joanne Ngeow; Margaret H Collins; Lisa J Martin; Philip E Putnam; Juan P Abonia; Keith Marsolo; Charis Eng; Marc E Rothenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

4.  Pediatric juvenile polyposis syndromes: an update.

Authors:  Sherry C Huang; Steven H Erdman
Journal:  Curr Gastroenterol Rep       Date:  2009-06

5.  Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation.

Authors:  Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2007-08-15       Impact factor: 11.025

6.  Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.

Authors:  Ramon Martinez; Veit Rohde; Gabriele Schackert
Journal:  J Neurooncol       Date:  2009-07-31       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.